Maryam Hami; Mehrdad Sarabi; Mehdi Hassanzade Daloee; Hassan Mehrad-Majd; Abdollah Firoozi; Niloofar Nourizadeh; Niloofar Nikpasand; Sara Naghizadeh Kashani; Mina AkbariRad
Abstract
Background and aim: Cardiac arrhythmia is common in end-stage renal disease (ESRD) patients, especially those undergoing hemodialysis. One of the most significant risk factors for cardiac arrhythmias is thought to be electrolytic abnormalities. This study aimed to assess the effect of hemodialysis on ...
Read More
Background and aim: Cardiac arrhythmia is common in end-stage renal disease (ESRD) patients, especially those undergoing hemodialysis. One of the most significant risk factors for cardiac arrhythmias is thought to be electrolytic abnormalities. This study aimed to assess the effect of hemodialysis on cardiac arrhythmias according to electrolytic disorders in chronic kidney disease (CKD) patients.Materials and methods: This cross-sectional study was conducted on ESRD patients who had undergone hemodialysis for at least six months. An electrocardiogram (ECG) and serum levels of sodium, potassium, calcium, and magnesium were checked before and after hemodialysis for all the patients. The data were entered and analyzed using SPSS software.Results: In this study, 96 patients were included. The most common arrhythmia was atrial fibrillation (AF) (22.9%). Our findings revealed that changes in serum potassium levels (p = 0.036) had a significant relationship with the occurrence of AF. There was a significant negative relationship between changes in serum calcium level and the QTc interval (r = -0.223 and p = 0.023). Furthermore, there was a significant positive relationship between changes in serum calcium levels and the QRS complex amplitude (r = 0.350 and p = 0.0001).Conclusion: ECG abnormalities, especially AF arrhythmias, are common in patients undergoing hemodialysis, which highlights the need for ECG monitoring both during and after hemodialysis.
Ahmad Nemati; Farkhonde Nikkhah; Mohammad Moshiri; Hanie Salmani Izadi; Leila Etemad
Abstract
SV (sodium valproate) is an antiepileptic drug that is often prescribed for epilepsy, bipolar disorders, and migraine. We reported an SV intoxicated case that cardiac and neurologic abnormalities were promptly responded to hemodialysis (HD). She ingested a large amount of SV (150 pills of SV 200mg) for ...
Read More
SV (sodium valproate) is an antiepileptic drug that is often prescribed for epilepsy, bipolar disorders, and migraine. We reported an SV intoxicated case that cardiac and neurologic abnormalities were promptly responded to hemodialysis (HD). She ingested a large amount of SV (150 pills of SV 200mg) for a suicide attempt. She was initially alert but her Glasco coma scale (GCS) decreased to 6 thought 11 hours. However, valproate (>150mg/l) and ammonia serum (164µg/dL) levels were not excessively elevated. The serial electrocardiography (ECG) showed QT prolongation and a signs of sodium channel block such as dominant R wave in AVR lead and T-wave inversion in the precordial leads. She had low level of calcium and potassium serum levels. Supportive treatment, charcoal, and L-carnitine, were not effective and HD was started due to the resistant cardiac and neurologic symptoms. After a 3-hour HD session, decreased GCS, pathological ECG findings, and laboratory abnormalities dramatically disappeared. In conclusion, HD is an effective and rapid response treatment for Valproate-induced loss of consciousness and life-threatening cardiac abnormality.
Hasan Ravari; Azin Banihashem; Mohammad Vejdani; Gholamhosein Kazemzadeh
Abstract
Vascular access failure is known as a principal cause of morbidity of end stage renal disease (ESRD) patients. The major reason for vascular access failure is the neointimal hyperplasia which leads to venous thrombosis and stenosis. The efficacy of different pharmacological therapies has been studied ...
Read More
Vascular access failure is known as a principal cause of morbidity of end stage renal disease (ESRD) patients. The major reason for vascular access failure is the neointimal hyperplasia which leads to venous thrombosis and stenosis. The efficacy of different pharmacological therapies has been studied in increasing the vascular access patency duration or decreasing the thrombosis of arteriovenous grafts or fistulas. In the current review, we reviewed the results obtained in different randomized control trials considering the efficacy of pharmacotherapy on the thrombosis rate and duration of vascular access grafts patency in HD patients.
Marzieh Rahimzadegan; Farshid Abedi; Seyed Abodolrahim Rezaei; Reza Ghadimi
Abstract
Human T-lymphotropic virus (HTLV-1) is an ancient pathogen for human being but arising and recognized recently. The routes of transmission are vertical (mainly by breastfeeding), unsafe sexual contacts and through contaminated blood components specially in whom need frequent and repeated blood ...
Read More
Human T-lymphotropic virus (HTLV-1) is an ancient pathogen for human being but arising and recognized recently. The routes of transmission are vertical (mainly by breastfeeding), unsafe sexual contacts and through contaminated blood components specially in whom need frequent and repeated blood transfusions such as permanent anemia due to blood loss in hemophilia and major thalassemia. Patients who should undergo hemodialysis in their lifelong are another instance for increased risk of HTLV-1 exposure. The main HTLV-1-associated diseases are tropical spastic tetraparesis (HAM/TSP), an inflammatory myelopathy and adult T-cell leukemia (ATL). Although HTLV-1 is scattered around the world, only in endemic areas where prevalence rate is more than 1%, viral burden of infection have accumulated. Japan, Southern and Central parts of Africa, Caribbean basin and Iran are examples of endemic areas of HTLV-1. In this article, a rapid and brief review of HTLV-1 virology, immunology and pathogenesis have emerged. In addition, a short debate has driven about current statues of HTLV-1 in Iran.